Citations

Clear

21 citation(s) found for "Shah, Manisha".

Response to Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer”
Konda, Bhavana , Sherman, Eric J. , Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2025 | Volume: 110 | Issue: 7 | Pages: e2425-e2426

10.1210/clinem/dgaf221 | PMID 40184489 Get It

Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Konda, Bhavana , Sherman, Eric J. , Morris, John C, Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 9, 2024 | Volume: 110 | Issue: 3 | Pages: 830-837

10.1210/clinem/dgae512 | PMID 39133806 Get It

Abstract Background This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. Methods Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. Results Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. Conclusion CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Abuzakhm, Sonia, Sukrithan, Vineeth , Fruth, Briant, Qin, Rui , Strosberg, Jonathan , Hobday, Timothy J. , Reidy‐Lagunes, Diane , Kindler, Hedy L. , Kim, George P., Knox, Jennifer J. , Kaubisch, Andreas , Villalona‐Calero, Miguel A. , Erlichman, Charles , Shah, Manisha H. , Strosberg, Jonathan R , Knox, Jennifer J , Sukrithan, Vineeth , Semrad, Thomas John , Chen, Helen

Mayo Clinic

Endocrine-Related Cancer | September 13, 2023 | Volume: 30 | Issue: 11 | Pages: No page available

10.1530/erc-22-0301 | PMID 37702588 Get It

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.
P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
Johnson, I., McCullough, K., Farrukh, F., Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Litzow, Mark R. , Shah, Manisha , Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew, Gangat, Naseema , Alkhateeb, Hassan B. , Hogan, William J. , Shah, M., Tefferi, Ayalew

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 443-444

10.1097/01.hs9.0000845064.44923.05 Get It

Wide Individual Heterogeneity in Antigen-Specific Immunity After Coronavirus Disease 2019 (COVID-19) Infection
Marty, Paige K. , Shah, Manisha , Keulen, Virginia Van, Erskine, Courtney L. , Peikert, T., Escalante, Patricio , Keulen, Virginia P. Van

Mayo Clinic

A33. BIOMARKERS, ALLERGY AND IMMUNE RESPONSES IN COVID-19 | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1285-A1285

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1285 Get It

Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients Receiving B-Cell Targeted Therapy
Marty, Paige K. , Shah, Manisha H. , Keulen, Virginia Van, Erskine, Courtney L. , Theel, Elitza S. , Escalante, Patricio , Peikert, T., Keulen, Virginia P. Van , Zeng, Hu , Specks, Ulrich

Mayo Clinic

C13. IMMUNE RESPONSES AND POTENTIAL INFLAMMATORY BIOMARKERS IN SARS-CoV-2 INFECTION | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3687-A3687

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3687 Get It

A Tissue Engineered Construct for Laryngeal Regeneration: A Proof‐of‐Concept Device Design Study
Shah, Manisha , Myers, Cheryl , McPhail, Michael, Neubauer, Juergen, Struthers, Jason D. , Madsen, Cathy S., Grandjean, Danielle, Zacharias, Stephanie R. C. , Tchoukalova, Yourka D. , Lott, David G , Tchoukalova, Yourka , Myers, Cheryl E , Lott, David G.

Mayo Clinic

The Laryngoscope | January 27, 2022 | Volume: 132 | Issue: S9 | Pages: No page available

10.1002/lary.30029 | PMID 35084750 Get It

Objectives/HypothesisDevelop a patient‐specific tissue engineered construct for laryngeal reconstruction following a partial laryngectomy.Study DesignBench and animal research.MethodsA construct made from a porous polyethylene scaffold shaped in a canine‐specific configuration and seeded with autologous canine adipose‐derived stem cells in fibrin glue was implanted in a canine following a partial laryngectomy. After 1 year, the construct was first evaluated in vivo with high‐speed imaging and acoustic–aerodynamic measures. It was then explanted and evaluated histologically.ResultsThe canine study at 1 year revealed the construct provided voicing (barking) with acoustic and aerodynamic measures within normal ranges. The canine was able to eat and breathe normally without long‐term support. The construct was integrated with epithelialization of all areas except the medial portion of the vocal fold structure. No anti‐infective agents were needed after the standard perioperative medications were completed.ConclusionThis study provided a successful first step toward developing a patient‐specific composite construct for patients undergoing partial laryngectomies.Level of EvidenceNA Laryngoscope, 132:S1–S11, 2022
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, Manisha H. , Benson, Al B. , Bergsland, Emily K. , Blaszkowsky, Lawrence S. , Brock, Pamela , Chan, J.K.C., Das, Satya , Dickson, Paxton V. , Fanta, Paul T. , Giordano, Thomas J. , Halperin, Daniel M. , He, Jin , Heaney, Anthony P. , Heslin, Martin J. , Kandeel, Fouad , Kardan, Arash , Khan, Sajid , Kuvshinoff, Boris W. , Miller, Kimberly D. , Reidy‐Lagunes, Diane , Salgado, Sarimar Agosto , Shaheen, Shagufta , Sussman, Craig, Trikalinos, Nikolaos A. , Uboha, N., Vijayvergia, Namrata , Lynn, Beth, Hochstetler, Cindy, Trikalinos, Nikolaos A , Goldner, Whitney Sears , Hálfdánarson, Þorvarður R. , Lieu, Christopher H. , Pillarisetty, Venu Gopal , Soares, Heloisa P. , Soulen, Michael C , Strosberg, Jonathan , Wong, Terence Z.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 839-868

10.6004/jnccn.2021.0032 | PMID 34340212 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Bible, Keith C. , Kebebew, Electron , Brierley, James D. , Brito, Juan P. , Clark, Thomas J. , Foote, Robert L. , Giordano, Thomas J. , Kasperbauer, Jan L. , Newbold, Kate, Rosenthal, M. Sara, Sawka, Anna M. , Shah, Manisha H. , Shaha, Ashok R. , Smallridge, Robert C., Wong-Clark, Carol K., Kasperbauer, Jan , Smallridge, Robert, Brito, Juan P , Cabanillas, Maria E. , Cristofano, Antonio Di , Nikiforov, Yuri E. , Randolph, Gregory William

Mayo Clinic

Thyroid® | March 17, 2021 | Volume: 31 | Issue: 3 | Pages: 337-386

10.1089/thy.2020.0944 | PMID 33728999 Get It

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, and researchers on published evidence relating to the diagnosis and management of ATC. Methods: The specific clinical questions and topics addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of the Task Force members (authors of the guideline). Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, targeted/systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues, including end of life. The guidelines include 31 recommendations and 16 good practice statements. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of ATC. While all care must be individualized, such recommendations provide, in our opinion, optimal care paradigms for patients with ATC.
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
Shah, Manisha H. , Sherman, Eric J. , Lorch, Jochen H. , Brose, Marcia S. , Godbert, Yann , Meurer, Marie, Tan, Daniel Shao-Weng , Patel, Jyoti D. , Yang, Luxi , Kherani, Jennifer , Wirth, Lori J. , Robinson, Bruce , Solomon, Benjamin , Kang, Hyunseok , Worden, Francis P. , Leboulleux, Sophie , Morris, John C., Owonikoko, Taofeek Kunle , Gautschi, Oliver , Cabanillas, Maria E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 3594-3594

10.1200/jco.2020.38.15_suppl.3594 Get It

3594 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer (MTC). Methods: Patients with RET-mutant MTC were enrolled to the Phase 1/2 LIBRETTO-001 trial (NCT03157128), a global, multicenter trial (16 countries, 89 sites). Following the Phase 1 dose escalation portion of the trial, patients received the recommended dose of 160 mg orally twice daily. Each cycle was 28 days. The primary endpoint was objective response rate (ORR) per RECIST 1.1. Secondary endpoints included duration of response (DoR) and safety. Per health authority agreement, the primary analysis set was defined as the first 55 consecutively enrolled patients previously treated with multikinase inhibitors cabozantinib and/or vandetanib. Patients naïve to cabozantinib and vandetanib treatment were analyzed separately. All analyses were based on a 16-Dec-2019 data cutoff date. Results: In the primary analysis set of prior cabozantinib and/or vandetanib-treated patients with MTC (n = 55), the ORR by investigator assessment was 62% (95% CI 47.7–74.6, n = 34/55) and the median DoR was not reached (95% CI 18.4 months–not estimable) despite a median follow-up of 14.8 months. In cabozantinib/vandetanib treatment-naïve patients (n = 88), the ORR by investigator assessment was 69% (95% CI 58.6–78.7, n = 61/88, including 2 responses pending confirmation). Of the 59 confirmed responding patients, with a median follow-up of 8 months, responses were ongoing for 57 responders at the time of the analysis. In the safety analysis set consisting of all selpercatinib dosed patients (N = 702), the most common treatment-related adverse events (TRAEs) that occurred in ≥15% of patients were dry mouth (33.3%), increased AST (24.5%), increased ALT (23.8%), hypertension (23.2%), diarrhea (19.7%), and fatigue (16.8%). Only 2% (14 of 702) of patients discontinued selpercatinib for TRAEs. Conclusions: Selpercatinib use was associated with marked and durable antitumor activity in prior cabozantinib and/or vandetanib-treated patients and in cabozantinib/vandetanib-naïve patients with RET-mutant MTC, with the majority of responses ongoing in both cohorts. Selpercatinib was well tolerated. Efficacy data assessed by independent review committee based on the 16-Dec-2019 data cutoff date will be presented. Clinical trial information: NCT03157128 .